West's 14% Q2 Beat, Raised Guidance, and Buybacks Are Changing the Debate

West is now being judged on growth quality, not just durability

West is no longer being judged only on how durable it is. After Q2 revenue of $872.3 million and adjusted EPS of $2.37, the debate shifted. Investors are now asking whether West deserves a premium because of stronger growth, or whether the stock is simply too expensive for a business whose longer-term sales growth has been moderate.

The quarter was solid, not theatrical. Revenue grew 13.8% year over year, adjusted EPS grew 13.9%, and management raised full-year guidance to $3.36 billion of revenue and $8.95 of adjusted EPS. In a post-rally market, though, that is enough to split opinion. Some investors see a company moving onto a higher earnings track. Others see a good business getting less forgiving valuation math.

That is why the bear case is showing up now. West shares jumped 13.4% over 90 days, are up roughly 35.85% over 3 months, and are up 43% over the past six months. Skeptics point to estimated sales growth of 2.6% for the next 12 months and a mediocre 5.7% compounded annual growth rate over the last five years in sales. The central question is no longer whether West is high quality. It is whether the recent rerating can be justified by durable growth, not just recency.

Q1 momentum, HVP mix, and buybacks strengthened the bull case

What changed is not just the top-line beat, but the quality behind it. The stronger setup was already visible in the first half of the year.

The mix shift is doing more of the work

Q1 already showed a stronger engine: revenue rose 21.0%, organic growth was 15.3%, and adjusted EPS rose 46.9%. That tells you the earnings expansion was not coming from timing alone. Proprietary Products grew 16% organically, the Biologics market group rose 29%, and High-Value Product Components now represent 49% of total revenue.

That matters because a better mix can improve both growth durability and margins. Management has also tied the company's strong win rate on complex biologics to barrier films such as FluroTec and NovaPure, noting that customers often need those materials and do not easily switch once a formulation is set.

Buybacks are reinforcing per-share growth

Capital return is making the math more attractive. West repurchased 1.2 million shares for $297.6 million in Q1 and 552,593 shares for $134.0 million in 2025. That does not guarantee a higher valuation, but it does support EPS and signal that management sees enough cash generation to fund growth while still returning capital.

The leadership transition is a watchpoint, not yet a weakness

The market is also watching whether this momentum survives the transition to Michel Lagarde as president and CEO in early June. Early process markers are at least neutral: West completed the SmartDose 3.5 mL rights transfer on July 1 and expanded its Dublin facility in March to support higher-volume injectable therapies. Those are not the main thesis, but they suggest operational execution is still moving forward.

The valuation debate is now about cash conversion and follow-through

The story improved, but the stock is no longer forgiving of lazy reasoning. After a sharp rally, investors tend to anchor to the first clean headline they see: a revenue beat and raised full-year guidance. That can encourage confirmation bias if investors assume one strong quarter proves a bigger rerating thesis.

Earnings strength has to translate into cash

The key tension in this quarter is not whether West beat expectations. It is whether that growth is converting into cash at the same rate. In Q2, free-cash-flow margin fell to 9.3% from 13.3% a year earlier, while operating margin remained 20.5%, in line with the prior year. That spread matters. Earnings can still look strong while cash conversion weakens because of working capital, capex, or both.

If cash conversion stays soft, the market may eventually pay a lower premium for each dollar of projected earnings. That is the cleanest way the bull case could get less attractive without a top-line miss.

The next signals that matter

The better-mix argument is still valid, but it only matters if it deepens customer stickiness and cash generation. Over the next few quarters, investors should focus on a short list of signals:

• whether HVP Components keep growing and remain a large and rising share of revenue, as High-Value Product Components now represent 49% of total revenue
• whether raised expectations hold, after raised full-year guidance in Q2
• whether capital return continues, alongside active buybacks
• whether cash conversion improves from the Q2 level

The case improved more than the simplicity of the trade

West has a better case than it did a year ago. Recent results showed a revenue beat and raised full-year guidance, the mix is shifting toward High-Value Product Components, and management is still actively buying back shares. That is a stronger combination than before.

But after a 13.4% 90 day share price return and strong momentum build over the past quarter, the setup is less straightforward. The rerating can continue, but it now needs follow-through in mix, earnings, and cash generation-not just another headline beat.